Castle Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Castle Biosciences

28/02/2023 23:42

* Castle Biosciences Inc  CSTL.OQ  reported a quarterly
adjusted
loss of 78 cents​​ per share for the quarter ended in December.
The mean expectation of eight analysts for the quarter was for a
loss of 84 cents per share.
    * Revenue rose 53.1% to $38.34 million from a year ago;
analysts
expected $37.16 million. 
    * Castle Biosciences Inc's reported EPS for the quarter was
a loss
of 78 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Castle Biosciences Inc shares had risen by 5.2% this
quarter.
    * The company reported a quarterly loss of $20.62 million.
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $48.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 11:42 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.84          -0.78          Beat
 Sep. 30 2022      -0.88          -0.77          Beat
 Jun. 30 2022      -0.76          -0.06          Beat
 Mar. 31 2022      -0.71          -0.97          Missed